What is the key to a robust immunity against SARS-CoV-2? According to a study recently published in The New England Journal of Medicine, it could be a previous SARS infection—more specifically, the one that spread across 29 countries between 2002 and 2004—plus vaccination.
Amgen announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.
The use of Pfizer Inc. and German partner BioNTech SE’s widely used Covid-19 vaccine marginally increases the risk of heart inflammation, but the risk is higher among those infected with the coronavirus, a study published on Aug. 25 in the New England Journal of Medicine showed.
Data and AI scientists must strive to eliminate bias from anything that touches patient care.
An experimental monoclonal antibody developed at the U.S. National Institutes of Health (NIH) prevented malaria for up to nine months in volunteers exposed to the disease-causing parasite in a small trial, researchers reported on Aug. 11 in the New England Journal of Medicine.
People who received the one-dose Johnson & Johnson Covid-19 vaccine may need a booster shot to fend off some of the worrisome coronavirus variants now spreading worldwide, a study suggests.
Two doses of Pfizer or AstraZeneca’s Covid-19 vaccine are nearly as effective against the highly transmissible Delta coronavirus variant as they are against the previously dominant Alpha variant, a study published on July 21 showed.
Scientists from the University of California, San Francisco have developed a tool that would give paralyzed persons who are unable to speak the ability to communicate through text that appears on a screen.
Intellia Therapeutics and Regeneron Pharmaceuticals shook the biotech and CRISPR world on June 26, announcing positive early data from the first-ever patients to have their DNA edited with an in vivo CRISPR/Cas9 therapy delivered systemically.
Pfizer Inc.’s oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized Covid-19 patients with pneumonia in Brazil, meeting the study’s main goal.